BCAX vs CHRS
BCAX: Bicara Therapeutics is developing a pipeline of bifunctional antibodies that precisely target and neutralize both EGFR and TGF-β pathways to improve treatment outcomes in solid tumors. CHRS: Coherus Oncology is a commercial-stage immuno-oncology company developing next-generation PD-1 inhibitors and checkpoint inhibitors for difficult-to-treat cancers including nasopharyngeal carcinoma, hepatocellular carcinoma, and head & neck squamous cell carcinoma.
Side-by-side fundamentals
| Metric | BCAX | CHRS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $27.96 | $1.43 | |
| Market cap as of 2026-07-23 | $1.9B | $227M | |
| P/E as of 2026-07-23 | n/a | 1.22 | |
| PEG as of 2026-07-23 | -0.16 | -0.12 | BCAX lower |
| Net margin as of 2026-07-23 | n/a | +397.3% | |
| Gross margin as of 2026-07-23 | n/a | +68.1% | |
| Operating margin as of 2026-07-23 | n/a | -366.6% | |
| ROE as of 2026-07-23 | -35.9% | +214.6% | CHRS higher |
| ROA as of 2026-07-23 | -33.8% | +50.3% | CHRS higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.66 | BCAX lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -76.3% | |
| Beta as of 2026-07-23 | 1.01 | 0.93 | |
| 1-year return as of 2026-07-22 close | +150.4% | +55.1% | BCAX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.